Previous 10 | Next 10 |
Gilead Sciences, Inc. ( NASDAQ: GILD ) shares have advanced from $61.45 to $80 since the beginning of October 2022, and the current price stands at $79.46. Gilead Sciences reported better-than-expected third-quarter results last week, and the company’s management updated ...
Summary Viatris looks like a great buying opportunity based on measures such as Price to Sales and Price to Free Cash Flow. The issue is that revenues from legacy brand sales are shrinking faster than new product revenues are climbing. Viatris management disposed of its biosim...
Summary In the latest quarter, ignoring the quite severe effects of the dollar's appreciation, Viatris' brands performed well. But even for biosimilars, Viatris is proving portfolio value in the sale of that portfolio for a more than 10x multiple. Viatris isn't a very exciting...
Summary As you can see, I nibbled on several different positions earlier this month. Seeing some of these dividend stalwarts with yields way above their historical average was too much to ignore. Sure prices may continue to fall further but as a long time dividend investor I know ...
Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022 PR Newswire PITTSBURGH , Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial ...
This is a great time to hunt for deals in the equity markets. Many quality stocks continue to fall, carried downward in part by the momentum of the broader market, and even among those that are somewhat defying the trend, some now trade at more reasonable valuations than they have in quite ...
Everybody loves a bargain. And in the current bear market, there are plenty of stocks to buy at a discount. We asked three Motley Fool contributors to identify dirt-cheap stocks to buy sooner rather than later. Here's why they chose Bristol Myers Squibb (NYSE: BMY) , Viatris ...
Summary In the third quarter of 2022, the Miller Income Strategy returned -7.34% (net of fees) versus a -0.68% return for the ICE BofA US High Yield Index. While the Fed is hiking the cost of money, the lower bound of the Federal funds target rate at the time of this writing is 3....
Summary Value investing comes back alive in declining markets, where the efficient-market hypothesis shows signs of inefficiencies. Graham's number is a useful tool to check how undervalued your stocks are in the present. I display 8 stocks out of my own portfolio and give my ...
Summary In September, we (my wife and I) received a dividend income total of $4,602.61. In total, the retirement accounts brought in a total dividend income amount of $1,413.32 or 31% of the dividend income total. In September, we rocked in six huge dividend increases, that re...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...